|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/19/22 Novo Integrated Sciences, Inc. 8-K:5,9 8/19/22 10:208K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 47K 5: R1 Cover HTML 47K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- form8-k_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 8K 3: EX-101.LAB XBRL Labels -- nvos-20220819_lab XML 96K 4: EX-101.PRE XBRL Presentations -- nvos-20220819_pre XML 64K 2: EX-101.SCH XBRL Schema -- nvos-20220819 XSD 12K 9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 10: ZIP XBRL Zipped Folder -- 0001493152-22-023591-xbrl Zip 16K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest reported): i August 19, 2022
i Novo Integrated Sciences, Inc.
(Exact name of registrant as specified in its charter)
| i Nevada | i 001-40089 | i 59-3691650 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification Number) |
i 11120 NE 2nd Street, i Suite 100, i Bellevue, i WA i 98004
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||
| i Common Stock, $0.001 par value | i NVOS | i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
C:
Item 5.07. Submission of Matters to a Vote of Security Holders.
On August 19, 2022, Novo Integrated Sciences, Inc. (the “Company”) held its 2022 virtual annual meeting of stockholders (the “Annual Meeting”) to vote on the following matters:
1. Election of Directors
Each of the following five nominees was elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next annual meeting of stockholders and until their successors have been duly elected and have qualified.
| Nominee | For | Against | Abstain | Broker Non- Votes | ||||||||||||
| Sarfaraz Ali | 19,737,900 | - | 19,617 | 959,575 | ||||||||||||
| Christopher David | 19,734,308 | - | 23,209 | 959,575 | ||||||||||||
| Alex Flesias | 19,433,375 | - | 324,142 | 959,575 | ||||||||||||
| Robert Mattacchione | 19,669,214 | - | 88,303 | 959,575 | ||||||||||||
| Michael Pope | 19,433,365 | - | 324,152 | 959,575 | ||||||||||||
2. Non-binding Advisory Vote on Executive Compensation
Stockholders voted to approve the following resolution, in accordance with the voting results listed below: “RESOLVED, that the stockholders of Novo Integrated Sciences, Inc. approve, on an advisory basis, the compensation paid to the Named Executive Officers, as disclosed in the proxy statement for the 2022 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Executive Compensation Summary section, compensation tables and narrative discussion, and other related disclosure.”
| For | Against | Abstain | Broker Non-Votes | ||||||||||
| 19,713,777 | 10,069 | 33,671 | 959,575 | ||||||||||
3. Non-binding Advisory Vote on Frequency of Executive Compensation Advisory Vote
Stockholders voted, on a non-binding, advisory basis, for every three years as the frequency for the Company’s executive compensation advisory vote, in accordance with the voting results listed below.
| One Year | Two Years | Three Years | Abstain | Broker Non-Votes | |||||||||||||
| 461,367 | 126,513 | 19,122,026 | 47,611 | 959,575 | |||||||||||||
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
C:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Novo Integrated Sciences, Inc. | ||
| Dated: August 19, 2022 | By: | /s/ Robert Mattacchione |
| Robert Mattacchione | ||
| Chief Executive Officer | ||
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 8/19/22 | None on these Dates | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/14/22 Novo Integrated Sciences, Inc. 424B4 1:3.7M M2 Compliance LLC/FA 10/07/22 Novo Integrated Sciences, Inc. S-1/A 105:18M M2 Compliance LLC/FA 9/13/22 Novo Integrated Sciences, Inc. S-1 101:17M M2 Compliance LLC/FA |